Randomised controlled trial
Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock
- Randomised controlled trial
- international
- multicentre
Authors' conclusion
The routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. The incidence of a composite of adverse events was higher with the use of the microaxial flow pump.
Study context
- Population
- Patients with STEMI and cardiogenic shock355 analysed
- Participants
- 360 patients
- Comparison
- Microaxial flow pump plus standard care vs standard care alone
- Microaxial flow pumpn = 179
- Standard caren = 176reference
- Primary endpoint
- Death from any cause
- Follow-up
- 180 days
Primary result
As reported in the abstract
Hazard ratio
0.74
95% CI 0.55–0.99
P = 0.04
Events by treatment group
Microaxial flow pump vs Standard care
HR 0.74 (95% CI 0.55–0.99); P = 0.04
Safety
| Outcome | Microaxial flow pump | Standard care | RR (95% CI) | |
|---|---|---|---|---|
| Composite safety end point (severe bleeding, limb ischemia, hemolysis, device failure or worsening aortic regurgitation) | 24.0% | 6.2% | 4.74 (2.36–9.55) | |
| Renal-replacement therapy | 41.9% | 26.7% | 1.98 (1.27–3.09) | |
| 0.10.31310Relative risk (log scale) |
Original publication
Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med. Published 7 April 2024. doi:10.1056/nejmoa2312572
Summarised from the published abstract; every number is checked against it